IKK2 inhibitors (AstraZeneca)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameIKK2 inhibitors (AstraZeneca)
Drug Alias NameIkappaB kinase 2 inhibitors (AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInhibitor of nuclear factor kappa-B kinase subunit beta inhibitorsNuclear factor NF-kappa-B complex inhibitors
TargetsInhibitor of nuclear factor kappa-B kinase subunit betaNuclear factor NF-kappa-B complex
Therapy Area/IndicationsAutoimmune DiseasesArthritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsAutoimmune DiseasesArthritis

Other Information

ATC CodeN/A
Related LinksN/A